Abstract:Signaling through the Rho family of small GTPases has been increasingly investigated for their involvement in a wide variety of diseases such as cardiovascular, pulmonary, and neurological disorders as well as cancer. Rho GTPases are a subfamily of the Ras superfamily proteins which play essential roles in a number of biological processes, especially in the regulation of cell shape change, cytokinesis, cell adhesion, and cell migration. Many of these processes demonstrate a common theme: the rapid and dynamic reorganization of actin cytoskeleton of which Rho signaling has now emerged as a major switch control. The involvement of dynamic changes of Rho GTPases in disease states underscores the need to produce effective inhibitors for their therapeutic applications. Fasudil and Y-27632, with many newer additions, are two classes of widely used chemical compounds that inhibit Rho kinase (ROCK), an important downstream effector of RhoA subfamily GTPases. These inhibitors have been successful in many preclinical studies, indicating the potential benefit of clinical Rho pathway inhibition. On the other hand, except for Rac1 inhibitor NSC23766, there are few effective inhibitors directly targeting Rho GTPases, likely due to the lack of optimal structural information on individual Rho-RhoGEF, Rho-RhoGAP, or Rho-RhoGDI interaction to achieve specificity. Recently, LM11A-31 and other derivatives of peptide mimetic ligands for p75 neurotrophin receptor (p75(NTR)) show promising effects upstream of Rho GTPase signaling in neuronal regeneration. CCG-1423, a chemical compound showing profiles of inhibiting downstream of RhoA, is a further attempt for the development of novel pharmacological tools to disrupt Rho signaling pathway in cancer. Because of a rapidly growing number of studies deciphering the role of the Rho proteins in many diseases, specific and potent pharmaceutical modulators of various steps of Rho GTPase signaling pathway are critically needed to target for therapeutic intervention in cardiovascular disease, neurological disorders, and cancer progression.

Rho family-associated kinases PAK1 and rock.

RhoA/Rho-kinase in the Cardiovascular System

Rho signaling research: history, current status and future directions

Targeting Rho GTPase Signaling Networks in Cancer

Signaling Through Rho GTPase Pathway As Viable Drug Target.

Advances in the Development of Rho-associated Protein Kinase (ROCK) Inhibitors.

RhoA-ROCK2 signaling possesses complex pathophysiological functions in cancer progression and shows promising therapeutic potential

Rho GTPases: Regulation and roles in cancer cell biology

Rho GTPases in cancer: friend or foe?

Rho-Rock Signal Pathway Regulates Microtubule-Based Process Formation Of Cultured Podocytes - A Rock Inhibitor Y-27632 Promoted Podocyte Process Elongation.

One Step Closer to Targeting RAS.

Biology of the p21-Activated Kinases

Gankyrin Plays an Essential Role in Ras-induced Tumorigenesis Through Regulation of the RhoA/ROCK Pathway in Mammalian Cells

Assay of Cdc42, Rac, and Rho GTPase Activation by Affinity Methods

Rho/Rho-associated Kinase Pathway in Glaucoma (Review).

Rho-Associated Protein Kinase (ROCK) Promotes Proliferation and Migration of PC-3 and DU145 Prostate Cancer Cells by Targeting LIM Kinase 1 (LIMK1) and Matrix Metalloproteinase-2 (MMP-2).

Rock the Rock of Atherosclerosis

RhoJ: an emerging biomarker and target in cancer research and treatment

PAK signaling in oncogenesis

Myosin light chain phosphatase is a downstream target of Rho-kinase in endothelin-1-induced transactivation of the TGF-β receptor

The Role of Fast-Cycling Atypical RHO GTPases in Cancer